KEYNOTE-859: Presentation by Dr. Kai-Keen Shiu
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Length: 03:55
Dr. Kai-Keen Shiu, Consultant Medical Oncologist at the UCL Cancer Institute, describes results from the KEYNOTE-859 trial for patients with locally advanced unresectable or metastatic HER2-negative gastric or GOJ adenocarcinoma expressing PD-L1 with a CPS ≥ 1 . 1
CPS = combined positive score; GOJ = gastro-oesophageal junction; HER2 = human epidermal growth factor receptor 2; PD-L1 = programmed death ligand 1
More information about KEYTRUDA® (pembrolizumab) in locally advanced unresectable or metastatic gastro-oesophageal cancer.
References
- Rha SY, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology. 2023 Nov; 24(11):1181-1195.
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.
